Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.43 |
| ▸ | SMO | Q99835 | 10/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312950 | 0.89 | MET (0.49) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4310500 | 0.88 | MAPK14 (0.52) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL5143321 | 0.87 | MCHR1 (0.48) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4317882 | 0.84 | MCHR1 (0.47) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4313857 | 0.83 | MAPT (0.47) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4313232 | 0.81 | MAPK14 (0.48) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4316662 | 0.80 | MCHR1 (0.46) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL4315927 | 0.79 | LMNA (0.46) | MAPK14SMOMCHR1CYP2C9KCNH2 | |
| SCHEMBL13783560 | 0.79 | EGFR (0.48) | MCHR1MAPT | |
| SCHEMBL4317670 | 0.74 | MCHR1 (0.46) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | MAPK14 2629/4885SMO 2438/4885MCHR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.